Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

GE Healthcare to Be Sole Distributor of Gyros' Nanoliter-Scale Immunoassay Platform in Japan

By BiotechDaily International staff writers
Posted on 20 Jul 2011
GE Healthcare Life Sciences (Little Chalfont, UK), a global provider of transformational medical technologies and services, has signed a sole distribution agreement with Gyros AB (Uppsala, Sweden), a developer of microfluidic technologies to miniaturize and automate immunoassays. Under the agreement, GE Healthcare becomes the sole distributor of the Gyros nanoliter-scale immunoassay platform in Japan.

Major biopharmaceutical companies and their service providers use the Gyros platform worldwide to improve productivity and efficiency when developing biotherapeutics and vaccines, generating time-critical workflows to meet regulatory demands.

Erik Walldén, CEO at Gyros, said, “The growing acceptance of our nanoliter-scale immunoassay platform within the global biopharmaceutical industry makes it imperative that we are represented within the Japanese market. We believe that this agreement with GE Healthcare Life Sciences will be a key factor in our success. As well as the clear commercial synergy between our product portfolios, we can be sure of providing the highest standards of service and support for our Japanese customers. We look forward to a highly successful collaboration.”

Hiroko Watanabe, general manager GE Healthcare Life Sciences, Japan, added, “We are delighted to have signed this agreement with Gyros which will help us expand our offering of value-added and innovative technologies to the biopharmaceutical industry in Japan. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry.”

Related Links:

GE Healthcare Life Sciences
Gyros



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.